Aura Biosciences, Inc.

NasdaqGM:AURA Stock Report

Market Cap: US$343.6m

Aura Biosciences Management

Management criteria checks 2/4

Aura Biosciences' CEO is Eli de los Pinos, appointed in Jan 2007, has a tenure of 19.08 years. total yearly compensation is $3.60M, comprised of 17.2% salary and 82.8% bonuses, including company stock and options. directly owns 0.44% of the company’s shares, worth $1.51M. The average tenure of the management team and the board of directors is 2.3 years and 4.9 years respectively.

Key information

Eli de los Pinos

Chief executive officer

US$3.6m

Total compensation

CEO salary percentage17.22%
CEO tenure19.1yrs
CEO ownership0.4%
Management average tenure2.3yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

Is Aura Biosciences (NASDAQ:AURA) In A Good Position To Deliver On Growth Plans?

Nov 26
Is Aura Biosciences (NASDAQ:AURA) In A Good Position To Deliver On Growth Plans?

Aura Biosciences: Bringing Not-Quite-Viruses Closer To Fruition In Cancer

Nov 15

Is Aura Biosciences (NASDAQ:AURA) In A Good Position To Deliver On Growth Plans?

May 03
Is Aura Biosciences (NASDAQ:AURA) In A Good Position To Deliver On Growth Plans?

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Jan 11
We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company

Sep 17

We're Hopeful That Aura Biosciences (NASDAQ:AURA) Will Use Its Cash Wisely

Sep 11
We're Hopeful That Aura Biosciences (NASDAQ:AURA) Will Use Its Cash Wisely

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Oct 03
We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Mar 28
Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Oct 01
We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Aura gains as JMP starts with Bullish view citing treatment platform

Jul 19

Aura Biosciences' AU-011 gets FDA fast-track status for bladder cancer

Jun 30

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Apr 10
Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

CEO Compensation Analysis

How has Eli de los Pinos's remuneration changed compared to Aura Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$106m

Jun 30 2025n/an/a

-US$101m

Mar 31 2025n/an/a

-US$95m

Dec 31 2024US$4mUS$621k

-US$87m

Sep 30 2024n/an/a

-US$83m

Jun 30 2024n/an/a

-US$81m

Mar 31 2024n/an/a

-US$79m

Dec 31 2023US$4mUS$586k

-US$76m

Sep 30 2023n/an/a

-US$71m

Jun 30 2023n/an/a

-US$68m

Mar 31 2023n/an/a

-US$63m

Dec 31 2022US$795kUS$555k

-US$59m

Sep 30 2022n/an/a

-US$55m

Jun 30 2022n/an/a

-US$52m

Mar 31 2022n/an/a

-US$51m

Dec 31 2021US$7mUS$432k

-US$46m

Sep 30 2021n/an/a

-US$40m

Jun 30 2021n/an/a

-US$33m

Mar 31 2021n/an/a

-US$29m

Dec 31 2020US$1mUS$395k

-US$30m

Compensation vs Market: Eli's total compensation ($USD3.60M) is above average for companies of similar size in the US market ($USD2.25M).

Compensation vs Earnings: Eli's compensation has increased whilst the company is unprofitable.

CEO

Eli de los Pinos (51 yo)

19.1yrs
Tenure
US$3,604,339
Compensation

Dr. Elisabet de los Pinos, also known as Eli, Ph D., is the Founder of Aura Biosciences, Inc. and serves as its Chief Executive Officer and President. Dr. de los Pinos has over ten years of experience in O...

Leadership Team

NamePositionTenureCompensationOwnership
Elisabet de los Pinos
Founder19.1yrsUS$3.60m0.44%
$ 1.5m
Conor Kilroy
Chief Legal Officer & Secretary1.8yrsUS$2.13m0.043%
$ 148.1k
Jill Hopkins
Chief Medical Officer & President of Research and Development2.3yrsUS$1.23m0.095%
$ 324.9k
Anthony Gibney
Chief Financial & Business Officerless than a yearno data0.090%
$ 308.0k
Amy Elazzouzi
Interim Principal Accounting Officer1.4yrsno data0.12%
$ 408.6k
Mark Plavsic
Chief Technology Officer2.4yrsno data0.29%
$ 981.4k
Patrick Nealon
Senior Vice President of Clinical Development Operations3.1yrsno datano data
Anthony Daniels
VP & Therapeutic Area of Head Ocular Oncology3.1yrsno datano data
Sabine Brookman-May
Senior VP & Therapeutic Area Head of Urologic Oncology1.3yrsno datano data
2.3yrs
Average Tenure
52.5yo
Average Age

Experienced Management: AURA's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Elisabet de los Pinos
Founderno dataUS$3.60m0.44%
$ 1.5m
Evangelos Gragoudas
Scientific & Clinical Advisorno datano datano data
Sapna Srivastava
Independent Director4.8yrsUS$202.38k0.017%
$ 56.8k
Jay Duker
Scientific & Clinical Advisorno datano datano data
Antony Mattessich
Independent Director4.4yrsUS$202.88k0.017%
$ 56.8k
Giovanni Mariggi
Independent Director6.8yrsno datano data
Richard Carvajal
Scientific & Clinical Advisorno datano datano data
David Johnson
Independent Chairman of the Board5.1yrsUS$231.38k0.50%
$ 1.7m
Arun Singh
Scientific & Clinical Advisorno datano datano data
Carol Shields
Scientific & Clinical Advisorno datano datano data
Brian Marr
Scientific & Clinical Advisorno datano datano data
Karan Takhar
Independent Director4.9yrsno datano data
4.9yrs
Average Tenure
54yo
Average Age

Experienced Board: AURA's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/23 18:34
End of Day Share Price 2026/02/20 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aura Biosciences, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan WollebenCitizens JMP Securities, LLC
Liisa BaykoEvercore ISI
Edward WhiteH.C. Wainwright & Co.